Starlab Neuroscience

Usage of Machine Learning in Brain Health

Aureli Soria-Frisch (PhD)

Director of Neuroscience BU



Outline

- Starlab, company context
- Overview: Machine Learning in Health applications
- Parkinsons' Decision Support System
- ADHD Digital Phenotypes
- Machine Learning for Consciousness Research
- Take home messages

Starlab – Company Context


A private R&D company based in Barcelona (since 2000)

Transforming Science into Technologies

Developing new products and services with profound and **positive social impact**



The Electrical Brain



Neuroscape, UCSF © Mishra J., Gazzaley A., 2015 Trends in Cognitive Sciences

STARLAB NEUROSCIENCE

The need - subjective evaluation symptoms Starlab

BRAIN HEALTH




YOUR	YOUR	YOUR	YOUR
NEIGHBOR	GRANDMA	FRIEND	DAD
WITH	WITH	WITH	WITH
EPILEPSY	ALZHEIMER'S	DEPRESSION	PARKINSONS
(50M PATIENTS WORLDWIDE)	(90M PATIENTS WORLDWIDE)	(240M PATIENTS WORLDWIDE)	(5M PATIENTS WORLDWIDE)

@aurelisofr

20% WORLD POPULATION

The need - CNS drug development costs



Source: Tufts Center for the Study of Drug Development, 2012


CNS HIGH RISK

\$604	
	\$741
	\$750
	\$792
	\$849
	\$604

Capitalized clinical development costs (in millions)

@aurelisofr


STARLAB BARCELONA | LIVING SCIENCE



Starlab - Research Program on Biomarkers

BRAIN EEG **Recording Electrical Activity** @aurelisofr

Starlab - Research Program on Biomarkers




Starlab Neuroscience


Machine Learning in Health applications



Health Industry



Health Industry



Roadmap Health Industry

About **80%** Healthcare Industry Participant believe 4 technologies namely AI, Big Data Analytics, mHealth and Wearables will be a game changer during 2019.

WHAT DOES IT MEAN FOR YOU?



Al for Healthcare IT application market to cross 1.7 billion by end of 2019 and projected to achieve a 68.5% CAGR from 2018-2022

AI IN HEALTHCARE



During 2019, more number of specialty-specific analytics solutions will gain prominence among providers. The healthcare data analytics market will cross \$68 billion by 2020.

HEALTHCARE DATA ANALYTICS



During 2019, digital health technologies catering to out-of-hospital settings will grow by 30% to cross \$25bn market globally. Key segments include RPM devices, Telehealth platforms, PERS, and mHealth.

DIGITAL HEALTH FOR OUT-OF-HOSPITAL SETTINGS

Access Actionable Intelligence

FROST & SULLIVAN

AI Health IT Market and Growth Opportunities, Forecast to 2022

Al for Medical Image Analysis-Companies-to-Action, 2018

US Healthcare Data Analytics Market, Forecast to 2020

Global Healthcare Data Analytics Companies-To-Action, 2017

Vision 2025—Healthcare in the Smart Home

Key Trends in Digital Health, Asia-Pacific, 2018

Growth Opportunities in the US Telehealth Market, Forecast to 2021

Survey Question – Tell us ONE key technology, you believe, will have the most profound impact on the Healthcare industry during 2019? Source: Frost & Sullivan Survey – Oct 2018 (n=244)

Throughout 2019, AI and machine learning will further evolve human and machine interaction. More specifically, AI will begin to see fruition, particularly in the imaging diagnostic, drug discovery, and risk analytics applications.

https://www.forbes.com/sites/reenitadas/2018/11/13/top-8-healthcare-predictions-for-2019/#

Health AI Publications

@ Bertalan MeskóThe Medical Futurist


TOTAL NUMBER OF STUDIES STUDIES PER SPECIALTY 7668 7871 RADIOLOGY SPORTS 40 354 2305 ENDOCRINOLOGY PEDIATRICS 397 129 DERMATOLOGY GASTROENTEROLOGY 187 PATHOLOGY NEUROLOGY 840 4651 2385 218 PULMONOLOGY 3233 1126 OPHTHALMOLOGY 321 2508 ONCOLOGY EMERGENCY 1581 1172 2537 SURGERY 1569 PRIMARY 203 2011 2012 2013 2014 2015 2016 2017 2018 2019 2005 2006 2007 2008 2009 2010 IVIE

MACHINE AND DEEP LEARNING STUDIES ON PUBMED.COM

Machine learning in Health (top 6 specialities): Neurology, Psychology, and Pathology

STARLAB BARCELONA | LIVING SCIENCE

@ Bertalan Meskó



Roadmap in Digital Brain Health

2014.09	- AliveCor detection of atrial fibrillation	PSYCHIATRY -
2016 .03. –	 — QbCheck diagnosis and treatment of ADHDv 	
2016.07	- InPen determining insulin dosage	
2016.10.	- Lumify ultrasound image diagnosis	ENDOCRINOLOGY
2016.11	One Drop Blood Glucose quantification of blood glucose levels	
2017.01.	Cantab Mobile memory assessment for the elderly	
2017.03	- EnsoSleep diagnosis of sleep disorders	
2017.05	- AmCAD-US analysis of thyroid nodules	RADIOLOGY -
2017.11.	- Lepu Medical detecting arrhythmias	
2017.12	- Subtle Medical medical imaging platform	
	BioFlux detecting arrhythmias	
2018 .01. –	- Bay Labs echocardiogram analysis	
2018.02	- Viz.ai stroke detection on CT	
	Arterys Inc liver and lung cancer diagnosis on CT and MRI	
	Empatica wearable for predicting epilepsy seizures	
	Cognoa autism diagnosis app	
2018.03	- Medtronic predicting blood glucose changes	
2018.04	- Idx detection of diabetic retinopathy	

18% FDA approved AI applications: Neurology, and Psychology

Biological Psychiatry: From subjective diagnosis to data-driven diagnosis

Digital Markers: Purpose?



Choong-Wan Woo, Luke J Chang, Martin A Lindquist & Tor D Wager 🏁

Digital Markers: Purpose?

Building better biomarkers: brain models in translational neuroimaging

- Risk assessment, conversion prediction and early detection
- Differential diagnosis and subtyping
- Predicting treatment outcome

Digital Markers: Purpose?

Building better biomarkers: brain models in translational neuroimaging


- Risk assessment, conversion prediction and early detection
- Differential diagnosis and subtyping
- Predicting treatment outcome

Starlab Neuroscience


Parkinsons' Decision Support System








DSS – Background



DSS – Background



STARLAB BARCELONA | LIVING SCIENCE

Biomarker Discovery - Parkinsons'

Multi-site Followup

- 1 Years
- 7 partners, 6 countries
- further development of Machine Learning based biomarkers

automate knowledge generation

Integrated platform for electrophysiology data analytics from acquisition to biomarker performance

POST-PRE (%)Alpha-2

system


integration

EEG biomarker discovery for Parkinson's

THE MICHAEL J. FOX FOUNDATION


STARLAB BARCELONA | LIVING SCIENCE

STARLAB NEUROSCIENCE



EEG features – starting point

A visualization of the EEG features analyzed suggests that there may be a potential use as a classification tool:





Features -> Power per Frequency Band


FFT of channel T3 for different groups (shadow areas = STE).


Number features = 14 channels x 13 freq bands Number features = 182

Feature selection – Classical vs Deep Autoencoders


LPSO Validation, SVM Class


- Classical: Filter, Wrapper
- Deep Autoencoder






Feature selection – Classical vs Deep Autoencoders





Feature selection – Classical vs Deep Autoencoders



Performance evaluation LPO

DLB vs PD -BandPower features-

	S1	S2	S3	S4	S5	S6	S7	S8	S9	S10	S11	S12 /	Ave AUC
S1	0.08	0.00	0.47	0.01	0.02	0.22	0.00	0.00	0.16	0.07	0.86	0.40	0.19
S2	0.94	0.47	1.00	0.90	0.67	0.91	0.07	0.06	0.96	0.72	0.98	0.91	0.72
S3	0.99	0.79	1.00	0.96	0.78	0.94	0.00	0.05	0.98	0.92	0.98	0.95	0.78
S4	0.40	0.19	0.66	0.25	0.23	0.51	0.03	0.06	0.57	0.37	0.86	0.56	0.39
S5	0.96	0.52	1.00	0.95	0.72	0.92	0.08	0.11	0.96	0.62	0.98	0.94	0.73
S6	0.81	0.11	0.98	0.54	0.36	0.82	0.00	0.00	0.95	0.40	0.98	0.79	0.56
S7	0.98	0.70	1.00	0.95	0.74	0.94	0.11	0.15	0.98	0.88	0.98	0.93	0.78
S8	0.95	0.57	1.00	0.91	0.65	0.91	0.01	0.19	0.97	0.69	0.98	0.91	0.73
S9	1.00	0.98	1.00	1.00	0.96	0.99	1.00	1.00	1.00	1.00	1.00	1.00	0.99
S10	1.00	0.99	1.00	1.00	0.96	0.98	0.73	0.99	1.00	1.00	1.00	1.00	0.97
S11	0.26	0.05	0.41	0.30	0.15	0.26	0.00	0.03	0.21	0.04	0.57	0.38	0.22
S12	1.00	0.93	1.00	0.97	0.83	0.96	0.02	0.38	0.99	0.96	0.98	0.98	0.83
S13	0.51	0.10	0.90	0.26	0.22	0.68	0.04	0.04	0.76	0.38	0.97	0.72	0.47
S14	0.99	0.90	1.00	0.98	0.85	0.96	0.45	0.50	0.99	0.95	0.99	0.97	0.88
Ave AUC	0.78	0.52	0.89	0.71	0.58	0.78	0.18	0.25	0.82	0.64	0.94	0.82	0.66

performance evaluation at individual level through LPSO [Airola et al 2010]:

- evaluate performance with small data sets
- AUC computation without representing the ROC space AUC Wilkoxon
- keep balance in the training (wrt LOSO)

Performance evaluation

N=118

		S	Decision system				
	AUC Wilkoxon	AUC ROC averaging	Acc	Sens	Spec	Ave Acc	Acc Global Norm.
HC vs. PD	88	88.22	94.19	88	100	61	68
HC vs. rest	76	76.26	88.01	76	100	68	68
LBD vs. PD	70	70.73	85.17	70	100	70	72
RBD vs. PD	80	80.07	89.93	80	100	66	77
RBD vs. PD+LBD	75	75.39	87.39	75	100	71	73

performance measure depends on the validation procedure and further normalization of scores - not always specified in the literature

Performance evaluation

N=118

		S	Decision system				
	AUC Wilkoxon	AUC ROC averaging	Acc	Sens	Spec	Ave Acc	Acc Global Norm.
HC vs. PD	88	88.22	94.19	88	100	61	68
HC vs. rest	76	76.26	88.01	76	100	68	68
LBD vs. PD	70	70.73	85.17	70	100	70	72
RBD vs. PD	80	80.07	89.93	80	100	66	77
RBD vs. PD+LBD	75	75.39	87.39	75	100	71	73

performance measure depends on the validation procedure and further normalization of scores - not always specified in the literature

Outperforming Classifiers


	AUC (optimal accuracy)	APP 1	APP 2
PD diagnosis	HC vs. PD	82 (91)	55 (77)
PD/DLB prognosis	PD vs. DLB	62 (81)	63 (82)
PD prognosis	PD vs. RBD	69 (84)	78 (89)
Conversion prognosis	RBD vs. PD+DLB	73 (87)	82 (91)
RBD diagnosis	HC vs. rest	73 (86)	-
	Average	72 (86)	69 (85)

 Validated in a larger data set (212 vs 118) in yellow

 Improved performance in a larger data set for conversion prognosis by going from spectral features to connectivity features (in red)

N=212

Classifier Scores as Biomarkers – Effect Size



Decision Support System - deployment

Clinical Translation and its problems

NE®	Liveview	Decision Support System 2 steps in Protocol	CHECK IMPEDANCE	00:02:02	00:02:02 ELAPSED	Save as patient0023	of De
7	FreeCosed					EyesOpen	
0	CONFIGURATION		Temporal window (sec.) 10	e Dec	ision Suppo	rt System	
न ा । च	F3 - WWWWW	manupulante	upmanumunation	Patient Na Protocol	Eyes	atient0023 Open 2:00 Closed 2:00	1 HAMANN'S
	F4 WWWWWW	monorton	Aparaman Aparal for services	NJ. RBD diagno:		Bill disputs	Manner
	a which y	a horizon and the second se	aller man and more son		515 0.21	Alpha Sym proposite) Mydminin
		www.www.www.	Mananahanganahan	ሳ Alpha Syn prog	mosis 0.12		Mylrowen
	5 65 - MMAAN	mannananananananananananananananananana	upproximation of a result	A PD prognos	is 0.02	Representer to the second seco	Mummen
	oz www.why	alphalapharanamalantamba	upman www.	la		Li L	Mamman
	P3 - WWWWW	weren warman warman here and a second s	upmenentareal resources	.∦ DLB progno	sis 0.55		Mannan
	P4 - WWWWWW	hormannon an	approximation and the second	^{/4}	CONFIRM		MMnyrrayn
				· · · · · ·			

| STARLAB BARCELONA | LIVING SCIENCE

STARLAB NEUROSCIENCE

Decision Support System - deployment

Clinical Translation and its problems

NE®	Liveview	Decision Support System 2 steps in Protocol	CHECK IMPEDANCE	00:02:02	00:02:02 ELAPSED	Save as patient0023	of De
7	FreeCosed					EyesOpen	
0	CONFIGURATION		Temporal window (sec.) 10	e Dec	ision Suppo	rt System	
न ा । च	F3 - WWWWW	manupulante	Monoralimentation	Patient Na Protocol	Eyes	atient0023 Open 2:00 Closed 2:00	1 HAMANN'S
	F4 WWWWWW	monomound	Aparaman Aparal for services	NJ. RBD diagno:		Bill disputs	Manner
	a which y	a horizontation and the second s	aller man and more son		515 0.21	Alpha Sym proposite) Mydminin
		www.www.www.	Monoralyangenances	ሳ Alpha Syn prog	mosis 0.12		Mylrowen
	5 65 - MMAAN	mannananaranakananakana kata kata kata kata kata k	upproximation of a result	A PD prognos	is 0.02	Representer to the second seco	Mummen
	oz www.why	alphalaphavaammalaanahan	upman www.	la		Li L	Mamman
	P3 - WWWWW	weren www.werender	upmenentareal resources	.∦ DLB progno	sis 0.55		Mann
	P4 - WWWWWW	hormannon an	approximation and the second	^{/4}	CONFIRM		MMnyrrayn
				· · · · · ·			

| STARLAB BARCELONA | LIVING SCIENCE


STARLAB NEUROSCIENCE

Starlab Neuroscience

ADHD Digital Markers



Digital Markers – ADHD data-driven diagnosis



Digital Phenotypes – ADHD

Building better biomarkers: brain models in translational neuroimaging


- Risk assessment, conversion prediction and early detection
- Differential diagnosis and subtyping
- Predicting treatment outcome

Starlab Neuroscience


Echo State Networks for EEG connectivity analysis



Recurrent Neural Networks - Echo State Networks




Recurrent Neural Networks - Echo State Networks




Hypothesis:

Recurrent neural networks and in particular Echo State Networks are able to detect complex chaotic synchronization between **temporal series**.


Exploring ESN Capabilities






Unsynchronized

Correlational Analysis



1.0 Corr Coef Using PGSQL Func

1.0 Corr Coef Using Pearson




Generalized Synchronzation

Unsynchronized

Exploring ESN Capabilities

We have constructed a continuous temporal signal consisting of a serisynchronized sequences interleaved with unsynchronized oper varying 'g' factor



Starlab Neuroscience

Echo State Networks as a Marker Generator



Background Data-Set



51 children aged 7-11

	ADHD (n = 21)	Control (n = 30)
Age in years	M 9.6 (SD 1.4)	M 9.3 (SD 1.5)
Male/Female	14 / 7	13 / 17
ADHD C/I	12 / 9	-
Medication (Yes/ No)	6 / 15	-

ADHD Inclusion Criteria:


- •Clinically diagnosed according to DSM-IV.
- •Not having comorbidity problems of mental retardation, autism, bipolar or psychotic disorders, history of epileptic seizures or any other relevant medical disorder.
- •Refrain 48h prior to the EEG assessment

Healthy Controls Inclusion Criteria:

- •Not having any psychopathology diagnosis, neither mental retardation or learning disorders
- •Not showing behavioral problems nor learning difficulties
- •Not having major family problems that could interfere with their participation in the study


Arousal: Psychological state of characterizing activation level wrt stimuli

Hypo-arousal Theory: The hypo-arousal theory is based on the principle that ADHD population looks for self-stimulation in order to achieve normal arousal levels through excessive activity.



ESN-based novel approach aiming at quantifying within subject dynamical differences between resting EO and EC

- Complex synchronization and non-stationary patterns change
- Between pairs of channels
- At specific brain rythms



	DCI							
	θ1	θ_2	α ₁	α ₂	β_1	β ₂	Υ ₁	Y ₂
C3	**				*			
Cz	**				**	*		
C4	**				*	**		
F3	**				**			
Fz	**				**			
F4	**				**	*		

Wilcoxon Ranksum (5%)

 Statistically significant differences in low theta and beta in every electrode

	DCI							
	θ	θ2	α ₁	α ₂	β_1	β ₂	Υ ₁	γ ₂
C3	**				*			
Cz	**				**	*		
C4	**				*	**		
F 3	**				**			
Fz	**				**			
F 4	**				**	*		


Wilcoxon Ranksum (5%)

 Statistically significant differences in low theta and beta in every electrode

Bonferroni-Holm Correction

 Statistically significant differences in low theta at C4, Cz and F3

	DCI								
	θ1	θ_2	α ₁	α ₂	β_1	β ₂	Υ ₁	Y ₂	
C 3									
C3 Cz C4	*								
C4	*								
F3	*								
F3 Fz									
F4									



STARLAB BARCELONA | LIVING SCIENCE

STARLAB NEUROSCIENCE

Starlab Neuroscience

LUMINOUS[®] H2020 FET project

Machine Learning for Consciousness Research

Aureli Soria-Frisch (PhD) Project Coordinator



03/17/2019


Consciousness will someday be electromagnetically measured and altered, and that the associated needed insights will prove crucial to the development cognitive






LUMINOUS H2020 FET PROJECT | 10/2/16 | STARLAB LIVING SCIENCE | BARCELONA

Luminous project Studying Consciousness in the Electrical Brain



Luminous project Changing Consciousness in the Electrical Brain?




LUMINOUS H2020 FET PROJECT | 10/2/16 | STARLAB LIVING SCIENCE | BARCELONA

56

Coma patients treatment

based on electrical stimulation



6/46 responders to treatment






STARLAB BARCELONA | LIVING SCIENCE

Coma patients treatment

based on electrical stimulation







6/46 responders to treatment

Can we predict who will respond positively?

Digital Markers – Minimal Conscious State

Building better biomarkers: brain models in translational neuroimaging

- Risk assessment, conversion prediction and early detection
- Differential diagnosis and subtyping
- Predicting treatment outcome
 - brain measures to predict who will respond to a particular treatment

Starlab Neuroscience

LUMINOUS®


TCS responders vs non-responders: EEG-based ML

Aureli Soria-Frisch (PhD) Project Coordinator



03/17/2019

EEG biomarkers - visualisation RBP feature



LUMINOUS H2020 FET PROJECT | 29/11/18 | STARLAB LIVING SCIENCE | BARCELONA


LUMINOUS PROJECT

61

EEG biomarkers - visualisation RBP feature

t-distributed stochastic neighbour embedding (t-SNE)

iterative minimisation of KL measure between distribution of distances in original and projected spaces




example MNIST

LUMINOUS H2020 FET PROJECT | 29/11/18 | STARLAB LIVING SCIENCE | BARCELONA

.9

EEG biomarkers - visualisation RBP feature




LUMINOUS H2020 FET PROJECT | 29/11/18 | STARLAB LIVING SCIENCE | BARCELONA

LUMINOUS PROJECT

63

Luminous project EEG biomarkers - classifiers



LUMINOUS H2020 FET PROJECT | 29/11/18 | STARLAB LIVING SCIENCE | BARCELONA


LUMINOUS PROJECT

EEG biomarkers - performance evaluation

Crossfold validation

- Area Under the Curve (AUC)
- Acc in subject classification at Equal Error Rate (EER) operation point
- Leave-One Subject Out (LOSO)

100 x LOSO





65


Starlab Neuroscience

Take home messages











Marta Castellano



Andrés Rojas



Aureli Soria-Frisch



David Ibáñez



Eleni Kroupi



Giulio Ruffini



THANKS!

